TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31818409
Drug: Pomalidomide and
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide and low‐dose dexamethasone
Study: 15207416
Drug: Risperidone 1
Normalized name: risperidone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 1 mg daily (in divided doses)
Study: 15207416
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg at bedtime
Study: 15207416
Drug: Promazine 50
Normalized name: promazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promazine 50 mg daily (in divided doses)
Study: 7976645
Drug: High oncotic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oncotic pressure (HOP; 26‐30 mmHg) treatment
Study: 7976645
Drug: Normal oncotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oncotic pressure (NOP; 22‐26 mmHg) treatment
Study: 2917587
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pipequaline
Study: 1101902
Drug: Diphenoxylate 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenoxylate 5 mg single oral dose
Study: 21453467
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate-topical corticosteroid combination
Study: 19700948
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 25-80 mg/day
Study: 15307699
Drug: Luohuo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luohuo capsule (LHC)
Study: 11175492
Drug: Etofibrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofibrate (500 mg twice daily)
Study: 11175492
Drug: Controlled-release niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release niacin (500 mg twice daily)
Study: 27269043
Drug: ubrogepant 25
Normalized name: Ubrogepant
DrugBank: Ubrogepant (DB15328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ubrogepant 25 mg
Study: 20722676
Drug: Lixisenatide 5
Normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 5 microg once daily
Study: 20722676
Drug: Lixisenatide 10
Normalized name: LIXISENATIDE 100MCG/ML INJ,SOLN,PEN,3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 10 microg once daily
Study: 20722676
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 microg once daily
Study: 20722676
Drug: Lixisenatide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 30 microg once daily
Study: 20722676
Drug: Lixisenatide 5
Normalized name: LIXISENATIDE 50/100MCG/MLX3ML START KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 5 microg twice daily
Study: 20722676
Drug: Lixisenatide 10
Normalized name: LIXISENATIDE 100MCG/ML INJ,SOLN,PEN,3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 10 microg twice daily
Study: 20722676
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 microg twice daily
Study: 20722676
Drug: Lixisenatide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 30 microg twice daily
Study: 18401602
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine digluconate gel (CHX)
Study: 16372263
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C supplementation (250 mg three times per week)
Study: 11113618
Drug: Novel antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel antioxidant supplements
Study: 9026680
Drug: Bed-time ultralente
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bed-time ultralente insulin (0.15-0.2 U/kg)
Study: 9026680
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.15-0.2 U/kg)
Study: 3370851
Drug: L‐menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐menthol
Study: 30152415
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care group (PCG)
Study: 23277307
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention with drug eluting stents (DES-PCI)
Study: 21623673
Drug: Somatostatin analog
Normalized name: Somatostatin analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analog (SA) treatment for 4 weeks
Study: 19257967
Drug: Thymus mature
Normalized name: THYMUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymus mature dendritic cells (mDC) in MG patients
Study: 11110851
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (3.4 g per day)
Study: 11110851
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (6.8 g per day)
Study: 11110851
Drug: Placebo (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9 g olive oil)
Study: 2186660
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam (0.5 mg/kg)
Study: 2186660
Drug: Oral trimeprazine
Normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimeprazine (4 mg/kg)
Study: 2186660
Drug: Oral pentobarbitone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentobarbitone (3 mg/kg)
Study: 450929
Drug: Methamphetamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (0.2 mg/kg or 0.3 mg/kg)
Study: 31486832
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 every 21 days) plus Sorafenib (400 mg orally twice daily)
Study: 19619102
Drug: PHC-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHC-based interventions for unemployed people, details on dosage and duration not available.
Study: 18035194
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin 0.3%/dexamethasone 0.1% (CD) otic suspension
Study: 18035194
Drug: Polymyxin B/neomycin/hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B/neomycin/hydrocortisone (PNH) otic suspension
Study: 14709948
Drug: Quetiapine (200-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (200-1200 mg/d)
Study: 16709552
Drug: Risperidone (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1-6 mg/d)
Study: 7859241
Drug: Tosufloxacin 150
Normalized name: tosufloxacin
DrugBank: Tosufloxacin (DB16850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosufloxacin 150 mg orally three times daily
Study: 7859241
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg orally twice daily
Study: 29119733
Drug: Fentanyl 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3.5 μg/kg via slow intravenous fluid line
Study: 29119733
Drug: Fentanyl 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3.5 μg/kg via direct injection (control group)
Study: 23138961
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management for stimulant abstinence plus treatment as usual
Study: 23138961
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with reinforcement for study participation only
Study: 16968575
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day plus metformin 1000 mg/day (RSG + MET)
Study: 16968575
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/day (up-titrated MET)
Study: 9352145
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human erythropoietin (rhEPO) at dosages up to 300 U/kg thrice weekly for 12 weeks
Study: 4065188
Drug: Femoxetine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (200 mg single dose)
Study: 4065188
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg single dose)
Study: 4065188
Drug: Femoxetine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (600 mg/day for 10 days)
Study: 4065188
Drug: Femoxetine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoxetine (600 mg/day for 10 days) with alcohol (EtOH)
Study: 26630391
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment for 8 weeks
Study: 25254301
Drug: Therapeutic rAd5
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic rAd5 HIV‐1 gag vaccine
Study: 15121485
Drug: Aprepitant 30
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 30 mg
Study: 15121485
Drug: Aprepitant 100
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 100 mg
Study: 15121485
Drug: Aprepitant 300
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 300 mg
Study: 11673771
Drug: Test yoghurt
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test yoghurt (200 g portion containing 5 g of a novel fat emulsion + 1 g milk fat)
Study: 7533904
Drug: Proteinase inhibitors
Normalized name: Proteinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteinase inhibitors
Study: 2438874
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid (AA) applied topically twice daily for 3 months
Study: 27786359
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy plus usual care (n=123; 76 in final analyses)
Study: 25810023
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine administered per rectum
Study: 25810023
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg MNTX given subcutaneously before 30 mg rectal morphine
Study: 11403367
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg q.d.
Study: 3124618
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin (400 micrograms 3 times a day)
Study: 3124618
Drug: Subcutaneous buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buserelin injection (200 micrograms once daily)
Study: 3124618
Drug: Intranasal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal and subcutaneous buserelin
Study: 31828590
Drug: Intraarticular corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroid injection (IACSI)
Study: 31828590
Drug: Intraarticular corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroid injection (IACSI) + Genicular nerve block (GNB)
Study: 30934041
Drug: Narrow-diameter titanium-zirconium
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter titanium-zirconium (Ti-Zr) alloy implants
Study: 30934041
Drug: Standard-diameter implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-diameter implants
Study: 30934041
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (narrow-diameter and standard-diameter implants)
Study: 21574983
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections matching active treatment
Study: 17352847
Drug: Adjunctive T3
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive T3
Study: 17241714
Drug: JE‐PIV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE‐PIV vaccine administered in either two or three intramuscular (IM) doses (6.0 or 12.0 mcg each)
Study: 25686143
Drug: RIN-150 (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIN-150 (rifampicin 150 mg and isoniazid 75 mg)
Study: 23727264
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg OCA
Study: 23727264
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg OCA
Study: 21078196
Drug: Family-focused cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused cognitive-behavioral therapy (CBT)
Study: 21078196
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control (no therapy)
Study: 18822906
Drug: Artificial menstrual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial menstrual cycle therapy (Control)
Study: 14519634
Drug: Adjuvant 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant 5-fluorouracil (5-FU) therapy
Study: 10768906
Drug: Intracoronary dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary dipyridamole (0.5 mg/kg bodyweight)
Study: 10768906
Drug: Conventional pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pretreatment (heparin 15,000 IU and aspirin 500 mg intravenously)
Study: 1358922
Drug: terazosin (2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: terazosin (2‐4 mg/day for 4 weeks)
Study: 4044461
Drug: Macrodantin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrodantin (100 mg at night)
Study: 4044461
Drug: Trimethoprim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (100 mg at night)
Study: 30636727
Drug: 4-week home-based
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week home-based treatment program including orthotics and strengthening exercises
Study: 29498348
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml blood orange juice providing 50 mg anthocyanins/d
Study: 29498348
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml blonde orange juice without anthocyanins
Study: 27561137
Drug: Public health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public health dose (16 kcal/kg/wk) of exercise for 12 weeks
Study: 27561137
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (4 kcal/kg/wk) of exercise for 12 weeks
Study: 24041737
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume polyethylene glycol (50 mL/kg, up to 2Lt/die) (Group B)
Study: 24041737
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume polyethylene glycol (25 mL/kg, up to 1Lt/die) (Group C)
Study: 24041737
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL (376 mg) of oral simethicone (Group D)
Study: 24041737
Drug: 25 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL/kg (up to 1Lt/die) of polyethylene glycol solution plus 20 mL (376 mg) of oral simethicone (Group E)
Study: 22513502
Drug: Tadalafil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (10 to 20 mg, increased based on effects and adverse reactions)
Study: 20551183
Drug: Antiangiogenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiangiogenic drugs (sorafenib [n = 10], sunitinib [n = 22])
Study: 18948239
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment (Group A)
Study: 18948239
Drug: No amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No amiodarone treatment (Group B)
Study: 11895046
Drug: P. ginseng
Approvals — FDA: no, EMA: no, PMDA: no
Description: P. ginseng 200 mg/d
Study: 6183864
Drug: Oral methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methoxsalen
Study: 6183864
Drug: Topical trioxsalen
Normalized name: Trioxsalen
DrugBank: Trioxsalen (DB04571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical trioxsalen
Study: 31725473
Drug: Risperidone plus
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone plus Propentofylline (300 mg/d)
Study: 22223180
Drug: Rilonacept (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (320 mg loading dose followed by 160 mg weekly)
Study: 17189087
Drug: Postural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural therapy
Study: 12170040
Drug: Intravenous parecoxib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous parecoxib, 20 mg
Study: 12170040
Drug: Intravenous parecoxib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous parecoxib, 40 mg
Study: 10094236
Drug: Antidepressants (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (at follow-up)
Study: 2378770
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg kg‐1 with adrenaline 5 micrograms ml‐1
Study: 2378770
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg kg‐1 without adrenaline
Study: 796476
Drug: Aspartame (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (2.7 g/day)
Study: 21718738
Drug: dTpa vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa vaccine (Boostrix(®))
Study: 18637602
Drug: Combined intrathecal
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intrathecal and epidural magnesium (50 mg of 5% Mg and 2% Mg at a rate of 100 mg/hr)
Study: 18637602
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 50 mg of 5% Mg
Study: 18637602
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 0.9% NaCl solution
Study: 17160911
Drug: Fenofibrate-statin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate-statin combination therapy
Study: 12585144
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and GBYL (Group B)
Study: 12585144
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and GBYL plus moxibustion (Group C)
Study: 12585144
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and placebo (Group A)
Study: 9730668
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, 0.2 IU/kg/body weight daily for 3 years
Study: 9730668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group 2) with 1-year observation followed by 3 years of GH treatment, 0.2 IU/kg/body weight daily
Study: 9730668
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (GH treatment)
Study: 127655
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus RAJI immunotherapy
Study: 23941313
Drug: Bupropion (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (active treatment)
Study: 23941313
Drug: Cognitive-behavioral smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral smoking cessation treatment (CBT)
Study: 22772870
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg
Study: 14565994
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training combined with GH administration
Study: 11370690
Drug: Raspberry leaf
Normalized name: Raspberry leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raspberry leaf tablets (2 x 1.2 g per day)
Study: 9234828
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg + Lisinopril 10 mg
Study: 9234828
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg + Lisinopril 10 mg
Study: 27113362
Drug: Tailored patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored patient education intervention (nurse-conducted medication counselling, information booklet, video, website, text message reminders)
Study: 22492424
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) 75 U/1.5 mL
Study: 22492424
Drug: Saline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1.5 mL)
Study: 15377480
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administration after transplantation
Study: 11486241
Drug: Uric acid,
Normalized name: SULFURIC ACID,TECHNICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid, 1,000 mg
Study: 11486241
Drug: Vitamin C,
Normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C, 1,000 mg
Study: 9658668
Drug: dotarizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: dotarizine (50 mg b.i.d.)
Study: 9658668
Drug: cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinnarizine (75 mg b.i.d.)
Study: 3394909
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline
Study: 31613050
Drug: Permethrin 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 2.5% with tea tree oil gel
Study: 28797867
Drug: Compression group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression group (CG) with circular-knit sleeves in compression class I (15-21 mm Hg) for daily wearing (n=23)